当前位置：
X-MOL 学术
›
Haematologica
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia.
Haematologica ( IF 8.2 ) Pub Date : 2021-09-23 , DOI: 10.3324/haematol.2021.279415 Srdan Verstovsek 1 , Ruben Mesa 2 , Moshe Talpaz 3 , Jean-Jacques Kiladjian 4 , Claire N Harrison 5 , Stephen T Oh 6 , Alessandro M Vannucchi 7 , Raajit Rampal 8 , Bart L Scott 9 , Sarah A Buckley 10 , Adam R Craig 10 , Karisse Roman-Torres 10 , John O Mascarenhas 11
Haematologica ( IF 8.2 ) Pub Date : 2021-09-23 , DOI: 10.3324/haematol.2021.279415 Srdan Verstovsek 1 , Ruben Mesa 2 , Moshe Talpaz 3 , Jean-Jacques Kiladjian 4 , Claire N Harrison 5 , Stephen T Oh 6 , Alessandro M Vannucchi 7 , Raajit Rampal 8 , Bart L Scott 9 , Sarah A Buckley 10 , Adam R Craig 10 , Karisse Roman-Torres 10 , John O Mascarenhas 11
Affiliation
Thrombocytopenia is common in patients with myelofibrosis and is a well-established adverse prognostic factor. Both of the approved Janus kinase (JAK) inhibitors, ruxolitinib and fedratinib, can worsen thrombocytopenia and have not been evaluated in patients with severe thrombocytopenia (.
中文翻译：
帕克替尼在骨髓纤维化合并严重血小板减少症患者中的回顾性分析。
血小板减少症在骨髓纤维化患者中很常见，是公认的不良预后因素。两种已获批准的 Janus 激酶 (JAK) 抑制剂鲁索替尼和 fedratinib 均可加重血小板减少症，尚未在严重血小板减少症患者中进行评估。
更新日期：2021-09-23
中文翻译：
帕克替尼在骨髓纤维化合并严重血小板减少症患者中的回顾性分析。
血小板减少症在骨髓纤维化患者中很常见，是公认的不良预后因素。两种已获批准的 Janus 激酶 (JAK) 抑制剂鲁索替尼和 fedratinib 均可加重血小板减少症，尚未在严重血小板减少症患者中进行评估。
京公网安备 11010802027423号